Anti-Human S1P Recombinant Antibody (TAB-H64)

Customer Review

There are currently no Customer reviews or questions for TAB-H64. Click the button above to contact us or submit your feedback about this product.

Citations

1. Campanella, Rolando, et al. "Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor to a systemic pathology." Cells 9.2 (2020): 294. https://doi.org/10.3390/cells9020294
   This research investigates the role of platelets (PLTs) in glioblastoma (GBM) microenvironment modulation through a process termed "tumor education." The study demonstrates that PLTs from GBM patients exhibit a more activated state compared to those from healthy donors, with higher expression of P-selectin even under basal conditions. These tumor-educated platelets (TEPs) carry and release significantly higher levels of pro-angiogenic and oncogenic factors including sphingosine-1-phosphate (S1P), vascular endothelial growth factor (VEGF), von Willebrand Factor (VWF), and their associated receptors. Functional assays revealed that GBM patient PLT-releasate significantly enhanced angiogenic activity in GBM endothelial cells, promoting the formation of more complex vascular networks compared to healthy donor PLT-releasate.
   Creative Biolabs provided Sonepcizumab, a monoclonal antibody that specifically recognizes S1P, which played a crucial role in detecting and quantifying this bioactive lipid both within platelets and in platelet releasate. This antibody enabled the researchers to demonstrate the enrichment of S1P in GBM platelets and establish its role in the pro-angiogenic effects observed. By facilitating the visualization and measurement of S1P, Creative Biolabs' reagent helped establish the concept of platelets as functional circulating carriers of oncogenic signals, advancing our understanding of GBM as a systemic pathology rather than merely a localized tumor.
2. Park, Ji-Hye, et al. "Synthesis and Characterization of an Amino-oxy-modified Sphingosine-1-Phosphate Derivative that Can Replace Thiolated-S1P in Competitive ELSIA." Bulletin of the Korean Chemical Society 41.4 (2020): 460-467. https://doi.org/10.1002/bkcs.11994
   This research focuses on the synthesis and characterization of a novel amino-oxy-modified sphingosine-1-phosphate (S1P) derivative that can effectively replace thiolated-S1P in competitive enzyme-linked immunosorbent assays (ELISA). S1P is an important signaling molecule that has emerged as a valuable biomarker for early diagnosis of conditions like osteoporosis and cancer. The researchers successfully synthesized the amino-oxy-modified S1P, which offers significant advantages over thiolated-S1P, including better stability against oxidation, improved water solubility, and the ability to be directly immobilized on microtiter plates without requiring additional linkers. Direct ELISA testing confirmed that the new derivative effectively binds to anti-S1P antibodies and provides comparable results to conventional thiolated-S1P references.
   Creative Biolabs provided the anti-human S1P antibody (biotin conjugated) that was essential for validating the functionality of the newly synthesized amino-oxy-modified S1P in direct ELISA assays. This antibody enabled the researchers to demonstrate that the novel S1P derivative could be recognized by commercially available S1P antibodies, confirming its potential as a viable replacement for thiolated-S1P in diagnostic applications. The company's high-quality reagents played a crucial role in establishing that the amino-oxy-modified S1P could be effectively immobilized on maleic anhydride-activated plates and used for quantitative S1P detection, potentially simplifying the manufacturing process of S1P-based diagnostic kits.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H64, RRID: AB_3112041)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Sonepcizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Sonepcizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "S1P"

Select a product category from the dropdown menu below to view related products.